MAP11

Across TCGA pan-cancer cohorts, MAP11 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAP11 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MAP11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP11 expression acts as an unfavorable survival marker, although some lineages such as OV and UCEC show a favorable association.

OV, LUAD, and UCEC are the cancer types where MAP11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.923	0.446	.019	20	view →
LUAD	DFS	Quartile	All	0.478	0.919	.009	14	view →
UCEC	DFS	Median	II,III,IV	1.000	0.497	.004	8	view →
GBM	OS	Median	All	0.374	0.652	.011	4	view →
PDAC	OS	Median	All	0.618	0.469	.035	3	view →
LSCC	OS	Median	II,III,IV	1.000	0.907	.025	1	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAP11–OV (DFS)

Open the OV breakdown →